Science & Innovation

Pipeline

Dorzagliatin

mGluR5

Poster and Presentation

Peer Reviewed Publications

Announcements and Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock Information

Corporate Communications

Portfolio Advisory Board

Senior Scientific Advisory Board

Media

Company News

Aug 01

2022

Hua Medicine Announces Multiple Personnel Appointments to Accelerate the Pace of Commercialization

Hua Medicine (the “Company”, stock code: 2552.HK) today announces that Mr. Qing Dong has been appointed as Vice President of the Pharmaceutical Commercialization Division of Hua Medicine. Mr. Qing Dong will be fully responsible for the development of dorzagliatin commercialization strategy and the strategic management of the pharmaceutical commercialization team to accelerate the adoption of dorzagliatin by Type 2 diabetes patients in China.

Jun 07

2022

Hua Medicine Announces Dorzagliatin can Restore Glucose Sensitivity and Early Phase Insulin Secretion in T2DM and GCK-MODY Patients at ADA 2022

Hua Medicine (the "Company", stock code: 2552.HK) today announces that several clinical findings were presented on its global first-in-class drug, glucokinase activator (GKA) dorzagliatin, at the 82nd American Diabetes Association (ADA) Annual Scientific Sessions. A post-hoc analysis that involved two Phase III clinical trials of dorzagliatin indicated that dorzagliatin can significantly improve early phase insulin secretion and glucose sensitivity of patients of Type 2 diabetes (T2D).

May 31

2022

Hua Medicine to Present Additional Clinical Results at ADA 2022

Hua Medicine (the "Company", SEHK stock code: 2552.HK) today announced that it will present several clinical results on its global first-in-class drug, glucokinase activator (GKA) dorzagliatin, at the 82nd American Diabetes Association (ADA) Annual Scientific Sessions.

May 13

2022

Hua Medicine Published Two Peer-Reviewed Papers in Nature Medicine, an International Top Medical Journal, on the Results of the Phase III Research of Dorzagliatin, a First-In-Class Investigational Diabetes Drug of Hua Medicine

Hua Medicine (the "Company", stock code on the main board of the Hong Kong Stock Exchange: 2552.HK) today announces that, two peer-reviewed papers on the Phase III clinical trial results of dorzagliatin, a glucokinase activator (GKA) and first-in-class investigational drug of the Company for the treatment of diabetes, were published online simultaneously by Nature Medicine, an international top medical journal. These two papers described and analyzed the clinical efficacy and safety characteristics of dorzagliatin monotherapy (SEED) in drug-na?ve Type 2 diabetes (T2D) patients and the combination therapy of dorzagliatin and metformin (DAWN) in patients who failed in metformin adequacy therapy for the treatment of T2D respectively.

Mar 16

2022

Hua Medicine Announces 2021 Annual Results

Hua Medicine (the "Company", Stock Code: 2552.HK) today announces the audited annual results of the Company and its subsidiaries for the year ended December 31, 2021 (the "Reporting Period"). The Reporting Period witnessed significant milestones in the commercialization process of dorzagliatin.

Feb 21

2022

Hua Medicine Announces Supply Agreement with WuXi STA for Commercial Manufacturing of Dorzagliatin

Hua Medicine (the "Company", Stock Code: 2552.HK) today announces a supply agreement with WuXi STA for the commercial manufacturing of dorzagliatin, a first-in-class oral therapy for type 2 diabetes (T2D). This commercial supply agreement between Hua Medicine and WuXi STA will further enhance their current collaboration.

Sep 26

2021

Researchers Present Key Research Results on Diabetes Remission of Dorzagliatin

Hua Medicine (the "Company", or "Hua Medicine", SEHK stock code: 2552.HK) today announced that at the 6th China BioMed Innovation and Investment Conference (the "CBIIC"), Professor Jianhua MA, Director of the Department of Endocrinology, Nanjing First Hospital, Standing Member of the Chinese Diabetes Society, as one of the principal researchers, presented the results from a clinical study called DREAM, which showed that dorzagliatin, a glucokinase activator and a first-in-class investigational drug of Hua Medicine, may make progress in diabetes remission.

Sep 23

2021

Hua Medicine's SEED Researchers to Present Key Research Results on Diabetes Remission at the China BioMed Innovation and Investment Conference

Hua Medicine (the "Company", SEHK stock code: 2552.HK) today announced that at the 6th China BioMed Innovation and Investment Conference to be held on September 25-27, 2021 in Suzhou, China (the "CBIIC"), select researchers participating in the Hua Medicine Phase III SEED Study ("SEED Study", also known as HMM0301)

Sep 15

2021

Hua and Sinopharm Announced Supply Chain Strategic Cooperation

On September 13, 2021, Hua Medicine (Shanghai) Ltd. (the "Hua Medicine", Stock Code: 2552.HK) has signed a supply chain strategic cooperation agreement with Sinopharm Group Co., Ltd. (the "Sinopharm", Stock Code: 1099). Under the agreement both companies will cooperate more closely in logistics warehousing, supply chain management and channel data analysis, and will jointly promote the commercialization of Hua Medicine's global first-in-class glucokinase activator (GKA), dorzagliatin, for its market launch in China.

About Us

Company Overview

Company History

Leadership Team

Portfolio Advisory Board

Senior Scientific Advisory Board

Partner

Media center

Research & Development

Inovation

Pipeline

Dorzagliatin

mGluR5

Company Publications

Peer Reviewed Publications

Investor Relations

Corporate Governance

Financial Report

Announcements & Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock information

Media

Company News

Media Releases

Video

Careers

Culture

Join Us

Product

HuaTangNing(華堂寧?)

Focus Us

Copyright ? 2024 Hua Medicine (Shanghai) Co., Ltd. 互聯(lián)網(wǎng)藥品信息服務(wù)資格證書編號(hào): （滬）-非經(jīng)營(yíng)-2022-0079
滬ICP備14036654號(hào)-1

滬公網(wǎng)安備 31011502013809號(hào) Privacy Statement Terms of Use

How we use cookies

Hua Medicine uses cookies to enable and improve the use of the website. By continuing to use the site, you consent to the use of these cookies. To learn more about cookies, please read our privacy statement.